Last reviewed · How we verify
NCT07419841
A Phase 1 Study of the Safety and Tolerability of CTX-10726
Phase 1 trial testing CTX-10726 in Gastroesophageal Cancer (GC) in 70 participants. Currently enrolling.
1 April 2028
Quick facts
| Lead sponsor | Compass Therapeutics |
|---|---|
| Phase | Phase 1 |
| Status | Recruiting now |
| Study type | INTERVENTIONAL |
| Allocation | non randomized |
| Design | single group |
| Masking | none |
| Primary purpose | treatment |
| Enrollment | 70 |
| Start date | 1 April 2026 |
| Primary completion | 1 April 2028 |
| Estimated completion | 1 November 2028 |
| Sites | 2 locations across United States |
Drugs / interventions tested
- CTX-10726 — full drug profile →
Conditions studied
- Gastroesophageal Cancer (GC) — all drugs for Gastroesophageal Cancer (GC) →
- Hepatocellular Carcinoma (HCC) — all drugs for Hepatocellular Carcinoma (HCC) →
- Endometrial Cancer — all drugs for Endometrial Cancer →
- Renal Cell Carcinoma (RCC) — all drugs for Renal Cell Carcinoma (RCC) →
Sponsor
Compass Therapeutics — full company profile →
Who can join
18 and older, any sex, with Gastroesophageal Cancer (GC) or Hepatocellular Carcinoma (HCC). Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
This is a Phase 1, open-label, first-in-human study of CTX-10726 monotherapy in patients with metastatic or locally advanced malignancies. The study will be conducted in 2 Cohorts: Cohort 1 Dose Escalation and Cohort 2 Dose Expansion.
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT07419841
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Gastroesophageal Cancer (GC)
Currently open trials in the same condition.
- NCT07277413 — A Study of IDE892 as Monotherapy and Combination in MTAP-deleted Advanced Solid Tumors · Phase 1 · recruiting
- NCT06687291 — Cognitive Impact Associated With Surgery For Gastric Or Esophageal Cancer · recruiting
- NCT06922279 — First Line gastroeSOphageal metastatiC canceR primAry and disTant (if Oligometastatic) lEsions-directed Radiotherapy, a · NA · active not recruiting
- NCT05632939 — ASKB589 in Combination With CAPOX and PD-1 Inhibitors in Patients With Advanced, and Unresectable G/GEJ Cancer. · Phase 1, PHASE2 · active not recruiting
Other Compass Therapeutics trials
Trials by the same sponsor.
- NCT05513742 — A Study of CTX-009 in Adult Patients With Metastatic Colorectal Cancer · Phase 2 · completed
- NCT03881488 — Study of CTX-471 as a Monotherapy or in Combination With Pembrolizumab in Patients Post PD-1/PD-L1 Inhibitors in Metasta · Phase 1 · completed
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT07419841 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Compass Therapeutics
- Last refreshed: 9 April 2026
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT07419841.